NeoGenomics launches NGS assay for AML

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

A research team at Oregon Health & Science University discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

January 09, 2026

Vol.52 No.1

Clinical Roundup

RNA splicing errors drive leukemia, UMiami-led study finds

A study from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, reveals how two genetic mutations, IDH2 and SRSF2, cooperate to erroneously splice RNA messages and disrupt the cell’s identity.

January 09, 2026

Vol.52 No.1

Drugs & Targets

Dark Blue Therapeutics acquired by Amgen for up to $840M

Dark Blue Therapeutics was acquired by Amgen.

January 09, 2026

Vol.52 No.1

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Sylvester researchers lead treatment overhauls for AML

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia is driving better survival and cure rates.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Researchers discover gene that could help improve treatment decisions in childhood leukemia

A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.

November 14, 2025

Vol.51 No.42

NeoGenomics launches NGS assay for AML

YOU MAY BE INTERESTED IN

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

RNA splicing errors drive leukemia, UMiami-led study finds

Dark Blue Therapeutics acquired by Amgen for up to $840M

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

Sylvester researchers lead treatment overhauls for AML

Researchers discover gene that could help improve treatment decisions in childhood leukemia

Renew today!

Subscriber content

Never miss an issue!

Login